Slow-Release Lanreotide Treatment in Acromegaly: Effects on Quality of Life

Sonino, Nicoletta; Scarpa, E; Paoletta, Agostino; Fallo, Francesco; Boscaro, Marco

doi:10.1159/000012326

Cited by 34 publications

(27 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hormone measurements and psychometric evaluation by means of self-rating scales were carried out at the baseline and after 1 and 2 months. Together with a significant decrease in GH and IGF-I, treatment with lanreotide significantly improved symptoms relating to psychological distress, well-being and social fears by employing the Symptom questionnaire, the Cognitive Scale of the screening List for Psychosocial Problems by Kellner and the Social Situation Questionnaire by Marks (21). Another small prospective study assessing various outcome measures including quality of life in nine patients with newly diagnosed acromegaly treated with octreotide-LAR for 6 months demonstrated significantly improvements in health perception and fatigue (22).…”

Section: Discussionmentioning

confidence: 99%

Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly

2006

View full text Add to dashboard Cite

Objective: Acromegaly has an important impact on quality of life (QOL). The aim of this study was to evaluate the associations of remission status and lanreotide treatment with QOL in patients with treated acromegaly, by the newly developed disease-generated acromegaly QOL questionnaire (ACROQOL). Design: Cross-sectional study. Methods: Fifty-two patients with treated acromegaly were recruited to complete the Chinese version of the ACROQOL translated and validated from the English version. These patients were divided into controlled and uncontrolled groups based on the latest remission criteria and further subdivided into four groups according to the present treatment with lanreotide or not. Comparisons between groups were analyzed. Results: There was no difference between controlled and uncontrolled groups in the ACROQOL scores of total score, both scales and psychological subscales. However, in the controlled group, present treatment with lanreotide, in comparison with no treatment, showed worse ACROQOL scores in total score (PZ0.021), psychological scale (PZ0.011), psychological subscale 'appearance' (PZ0.032) and 'personal relations' (PZ0.010). Conclusions: The lanreotide treatment was negatively associated with QOL in biochemically controlled acromegalic patients, especially in the psychological aspect.European Journal of Endocrinology 155 831-837

show abstract

Section: Discussionmentioning

confidence: 99%

Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly

2006

View full text Add to dashboard Cite

show abstract

“…Only two studies investigated the effects of SSTA on QoL and concluded that improvement of symptoms relating to psychological distress, well-being, social fears, and QoL occurs after treatment with Lanreotide (18,19). However, these studies did not compare the effects on QoL with other treatment modalities.…”

Section: Introductionmentioning

confidence: 99%

Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly

Postma

Netea‐Maier²,

Berg³

et al. 2012

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: To assess the influence of long-acting somatostatin analogs (SSTA) after initial pituitary surgery on long-term health-related quality of life (HR-QoL) in relation to disease control in patients with acromegaly. Design: This is a cross-sectional study in two tertiary referral centers in The Netherlands. Patients and methods: One hundred and eight patients with acromegaly, in whom transsphenoidal (nZ101, 94%) or transcranial (nZ7, 6%) surgery was performed. Subsequently, 46 (43%) received additional radiotherapy and 41 (38%) were on postoperative treatment with SSTA because of persistent or recurrent disease at the time of study. All subjects filled in standardized questionnaires measuring HR-QoL. Disease control at the time of study was assessed by local IGF1 SDS. Results: IGF1 SDS were slightly higher in patients treated with SSTA in comparison with patients without use of SSTA (0.85G1.52 vs 0.25G1.21, PZ0.026), but the percentage of patients with insufficient control (IGF1 SDS O2) was not different (17 vs 9%, PZ0.208). Patients using SSTA reported poorer scores on most subscales of the RAND-36 and the acromegaly QoL and on all subscales of the multidimensional fatigue inventory-20. A subgroup analysis in patients with similar IGF1 levels (SSTAC, nZ26, IGF1 SDS 0.44G0.72 vs SSTAK, nZ44, IGF1 SDS 0.41G0.65) revealed worse scores on physical functioning, physical fatigue, reduced activity, vitality, and general health perception across all HR-QoL questionnaires in patients treated with SSTA. Conclusion: QoL is impaired in association with the need for prolonged postoperative therapy by SSTA in patients with acromegaly despite similar IGF1 levels.

show abstract

“…Symptoms and morbidity associated with acromegaly have a significant impact on patients’ health-related quality of life (HRQoL), but few studies have taken HRQoL into account as a measuring instrument for patients with this condition [1]. Diagnosis of acromegaly is often delayed by several years, when changes in appearances as well as in many internal tissues may not be reversible, even after successful treatment.…”

Section: Introductionmentioning

confidence: 99%

Quality of Life in Acromegaly

Webb¹

2006

Neuroendocrinology

View full text Add to dashboard Cite

Acromegaly is a disease with an important impact on health-related quality of life (HRQoL). Cross-sectional evaluation of HRQoL in patients with acromegaly using generic questionnaires and the specific questionnaire AcroQoL has confirmed severe impairment; active disease, female gender, ageing, disease duration, joint symptoms and prior radiotherapy are associated with worse HRQoL. The most affected dimension is appearance and the least affected, personal relations; comparable results have been observed in Spanish, Dutch, German, English and Turkish speaking patients. Patients with active acromegaly show a worse score (mean range 43–56) than those in remission (mean range 65–71). In longitudinal studies, in patients with stable acromegaly, no change was observed on retesting at 1 month, demonstrating a good test-retest reliability. In patients with active acromegaly, after 6 months of treatment, an improvement in the AcroQoL score was observed (56 ± 20 to 66 ± 18; p < 0.01). The internal consistency of AcroQoL was good (Cronbach’s α >0.7). No correlation between AcroQoL and insulin-like growth factor-I/growth hormone levels was observed, even though a trend was found for the most affected dimension (appearance) and insulin-like growth factor-I (p = 0.051). In summary, HRQoL is severely affected in acromegaly, even in patients with controlled disease. Thus, to optimise management, not only biochemical and radiological parameters but also dimensions that reflect HRQoL should be evaluated in acromegaly.

show abstract

Slow-Release Lanreotide Treatment in Acromegaly: Effects on Quality of Life

Cited by 34 publications

References 15 publications

Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly

Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly

Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly

Quality of Life in Acromegaly

Contact Info

Product

Resources

About